A practical reference on Agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-27 and is reviewed periodically as new material appears.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility class | Soluble in water and DMSO | Dissolves readily |
| Typical storage temperature | -20 °C or lower | Long-term, desiccated |
| Standard purity method | Reverse-phase HPLC | Area normalization |
| Freeze-thaw guidance | Limit to three cycles | Aliquot in advance |
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
== Sources == This article incorporates text from a free content work. Licensed under CC BY 4.0 (license statement/permission). Text taken from World Food and Agriculture – Statistical Yearbook 2025, Food and Agriculture Organization of the United Nations. This article incorporates text from a free content work. Licensed under CC BY 4.0 (license statement/permission). Text taken from The State of Food Security and Nutrition in the World 2026, Food and Agriculture Organization of the United Nations.
=== Breakthrough and Liberation === On the night of June 25th, 1944, the German blockade was finally lifted as the Red Army's Operation Bagration reached the area. Small groups of partisans successfully navigated their way through German minefields and patrols to link up with Soviet forces on June 27th, 1944. Following the link-up, the brigade assisted the Red Army in clearing the remaining German Stragglers from the forests.
=== EC 2.5: alkyl and aryl transferases === EC 2.5 relates to enzymes that transfer alkyl or aryl groups, but does not include methyl groups. This is in contrast to functional groups that become alkyl groups when transferred, as those are included in EC 2.3. EC 2.5 currently only possesses one sub-class: Alkyl and aryl transferases. Cysteine synthase, for example, catalyzes the formation of acetic acids and cysteine from O3-acetyl-L-serine and hydrogen sulfide: O3-acetyl-L-serine + H2S
== Activation == Chymotrypsinogen must be inactive until it gets to the digestive tract, in order to prevent damage to the pancreas or any other organs. It is activated by another enzyme called trypsin. The active form is called π-chymotrypsin and is used to create α-chymotrypsin. Trypsin cleaves the peptide bond in chymotrypsinogen between arginine-15 and isoleucine-16. This creates two peptides within the π-chymotrypsin molecule, held together by a disulfide bond. One π-chymotrypsin acts on another by breaking a leucine and serine peptide bond. The activated π-chymotrypsin reacts with other π-chymotrypsin molecules to cleave and remove two dipeptides: serine-14–arginine-15 and threonine-147–asparagine-148. This reaction produces α-chymotrypsin. The yield of α-chymotrypsin can be affected by inhibitors such as hydrocinnate and also by pH, temperature and calcium chloride. The activation process can be studied using fluorescence probe 2-p-toluidinylnaphthalene-6-sulfonate (TNS). TNS forms covalent bonds with chymotrypsinogen and as the bonds break to form chymotrypsin in the presence of trypsin, the fluorescence increases.
Sources: en.wikipedia.org
Gives aid to "Catholic Communications" which produces TV and radio programs explaining the Catholic faith to Catholics and non-Catholics alike; annual pilgrimages to shrines; prayer card distributions; conducts picnics, bus trips, socials, etc.
== Treatment == The treatment of calciphylaxis requires a multidisciplinary approach, using the knowledge of nephrologists, plastic surgeons, dermatologists, and wound care specialists working together to manage the disease and its outcomes.
The under-five mortality rates plunged due to immunization against pneumonia, diarrhea, and measles. The EPI moved its focus onto integration of vaccination into broader primary health care system (specifically, maternal and child health services), continuing the theme of improving healthcare for those who already get some. However, global DTP3 coverage stagnated around 85%. The EPI also had to navigate obstacles such as supply chain disruptions caused by many disease outbreaks and vaccine hesitancy. The COVID-19 pandemic had greatly disrupted regular immunization services, with a severe decrease in DTP3 rates during 2020–2023. Outbreaks of new diseases such as COVID-19 and Zika also showed that the EPI needs to be able to deliver not only well-established vaccines, but also new vaccines for new diseases before too many are infected.
Sources: en.wikipedia.org
George Galloway (born 16 August 1954) is a British politician, broadcaster, and writer. He has been leader of the Workers Party of Britain since he founded it in 2019, and is a former leader of the Respect Party. Until 2003, he was a member of the Labour Party. From 1987 to 2010, from 2012 to 2015, and briefly in 2024, Galloway served as Member of Parliament (MP) for five different constituencies. As of 2026, he is living in "self-imposed exile" in Russia. Galloway was born in Dundee, Scotland. After becoming the youngest ever chair of the Scottish Labour Party in 1981, he was general secretary of the charity War on Want from 1983 until his election as MP for Glasgow Hillhead at the 1987 general election; he was re-elected three times. The Labour Party expelled him in 2003 due to comments he made in opposition to the invasion of Iraq. Galloway joined the Respect Party in 2004, and was its leader from 2013 to 2016. He was elected as MP for Bethnal Green and Bow at the 2005 general election. After losing in the neighbouring constituency of Poplar and Limehouse at the 2010 general election, he regained a parliamentary seat at the 2012 Bradford West by-election, only to lose it at the 2015 general election. He unsuccessfully stood as an independent candidate at the 2017 and 2019 general elections. Galloway then founded the Workers Party of Britain, and stood unsuccessfully for the party at the 2021 Batley and Spen by-election. Galloway won the 2024 Rochdale by-election. He lost the seat at the 2024 general election.
== Pharmacokinetics == Some pharmacokinetic data on hyperforin is available for an extract containing 5% hyperforin. Maximal plasma levels (Cmax) in human volunteers were reached 3–4 hours after administration of an extract containing 14.8 mg hyperforin. Biological half-life (t1/2) and mean residence time were 9 hours and 12 hours, respectively, with an estimated steady state plasma concentration of 100 ng/mL (approx. 180 nM) for 3 doses per day. Linear plasma concentrations were observed within a normal dosage range and no accumulation occurred. In healthy male volunteers, 612 mg dry extract of St. John's wort produced hyperforin pharmacokinetics characterized by a half-life of 19.64 hours.
==== United States ==== ETH-LAD is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
Sources: en.wikipedia.org
Cold storage at minus twenty degrees Celsius or below is typical, with desiccant and protection from light. The solid form is far more stable than any solution.
Repeated freeze-thaw cycles, alkaline pH, and exposure to light or oxygen are the main drivers. Moisture uptake by the solid also matters.
Mass spectrometry provides the strongest single identity check by matching the observed molecular ion to the expected value. Chromatographic retention time alone is not sufficient.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.